GlaxoSmithKline Plc (GSK)

40.20
0.20 0.50
NYSE : Health Technology
Prev Close 40.00
Open 40.17
Day Low/High 40.15 / 40.24
52 Wk Low/High 34.52 / 44.53
Volume 278.80K
Avg Volume 3.50M
Exchange NYSE
Shares Outstanding 2.48B
Market Cap 99.27B
EPS 0.80
P/E Ratio 22.92
Div & Yield 2.14 (5.25%)

Latest News

Novartis Agrees to Buy AveXis in $8.7 Billion Deal

Novartis Agrees to Buy AveXis in $8.7 Billion Deal

The acquisition is a big move for Novartis CEO Vas Narasimhan, who took the helm in February.

Blackberry, SkyWest, Apache: 'Mad Money' Lightning Round

Blackberry, SkyWest, Apache: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Blackberry, SkyWest, Apache, Philip Morris International, PetMed Express, Iron Mountain, Novartis.

Behind the Selloff: Cramer's 'Mad Money' Recap (Friday 4/6/18)

Behind the Selloff: Cramer's 'Mad Money' Recap (Friday 4/6/18)

This market is deceptive and you need to recognize your sense of timing is not infallible. So, adjust your scales and get ready for next week, says Jim Cramer.

If Stocks Don't Pop on All This Deals News Investors Better Look Out Below

If Stocks Don't Pop on All This Deals News Investors Better Look Out Below

M&A activity kicks into high gear going into the final days of the first quarter. If the broader stock market doesn't pop on this news, it would be a red flag.

4 Strong Buy Biotech Stocks Poised to Explode

4 Strong Buy Biotech Stocks Poised to Explode

Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.

The Dow Plunges Into the Close of Trading on Tuesday

The Dow Plunges Into the Close of Trading on Tuesday

Cooling tensions with China aren't enough to save investors on Tuesday.

Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday

Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday

With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.

Facebook, Novartis, GSK, Uber and Deutsche Bank - 5 Things You Must Know

Facebook, Novartis, GSK, Uber and Deutsche Bank - 5 Things You Must Know

U.S. stock futures rise and global stocks extend their rally; Novartis to sell 36.5% stake in joint venture to partner GSK for $13 billion; Facebook's Mark Zuckerberg won't face U.K. lawmakers.

Global Stocks Ride Wall Street Wave as U.S.-China Trade Talks Tempt Bulls

Global Stocks Ride Wall Street Wave as U.S.-China Trade Talks Tempt Bulls

Wall Street's best day in nearly three years has global stocks on the move Tuesday, with U.S.-China trade talks and a wave of late quarter M&A boosting markets around the world.

Global Stocks Tumble as China Fires Back in Trump Trade War

Global Stocks Tumble as China Fires Back in Trump Trade War

Global stocks tumbled, with markets in Asia losing all of their year-to-date gains, as China declared it's "not afraid" of an escalating trade war with the United States following President Trump's decision to target $50 billion in China-made goods.

GlaxoSmithKline Looks Poised for an Upside Move

GlaxoSmithKline Looks Poised for an Upside Move

GSK is still below the declining 200-day moving average line but a rally of $2 will challenge the line.

GSK Announces Positive EU Approval For Labelling Update To Relvar Ellipta In Patients With Asthma

GSK Announces Positive EU Approval For Labelling Update To Relvar Ellipta In Patients With Asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI),...

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.

Big Pharma, Big Blimps and 3 Other Names That Look Good Short

GSK, EXPE, GT, UHAL and UBNT were all recently were downgraded by TheStreet's Quant Ratings service.

GSK Submits Landmark IMPACT Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta

GSK Submits Landmark IMPACT Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CG, FLO, GNW, IART, LITE, MX, PDVW, PFPT, STO, TTWO Downgrades: AINV, BCO, BZH, CRCM, GSIT, GSK, IESC, ISRL, MLAB, MTCH, NEU, NNN, PZN, SGA Initiations: TRVG Read on to get TheStreet Quant Ratings' detailed report:

GSK Announces CHMP Positive Opinion For Labelling Update To Relvar Ellipta In Patients With Asthma

GSK Announces CHMP Positive Opinion For Labelling Update To Relvar Ellipta In Patients With Asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion...

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.

Look How Overbought This Market Is

In my "what if" scenario for the Nasdaq, no matter what numbers I plugged in, the Momentum Indicator went down.

GSK Submits Landmark IMPACT Data To US Regulatory Authority To Support Expanded Label For Trelegy Ellipta

GSK Submits Landmark IMPACT Data To US Regulatory Authority To Support Expanded Label For Trelegy Ellipta

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta...

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Nascar champion Danica Patrick talks about not being a gear head, her business ventures and how migraines have affected her life.

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation In Europe For The Treatment Of COPD

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation In Europe For The Treatment Of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol,...

When Will the Indexes Care?

Trying to find the answer to this often-asked question.

European, Wall Street Futures Slip; Dollar Dips as Trump Hits China on Trade

European, Wall Street Futures Slip; Dollar Dips as Trump Hits China on Trade

European and U.S. stocks are expected to drift lower Thursday as the dollar continues to bear the brunt of global uncertainty on trade and tax policy.

GlaxoSmithKline Wins FDA Approval to Develop 'Breakthrough' Blood Cancer Drug

GlaxoSmithKline Wins FDA Approval to Develop 'Breakthrough' Blood Cancer Drug

The FDA cleared GSK's new drug for fast-track development with quicker regulatory review.

GSK Study Demonstrates Superiority Of Anoro Ellipta To Stiolto Respimat In Improving Lung Function In Chronic Obstructive Pulmonary Disease

GSK Study Demonstrates Superiority Of Anoro Ellipta To Stiolto Respimat In Improving Lung Function In Chronic Obstructive Pulmonary Disease

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA)...

Bad Day for Dollar and Healthcare

What stocks benefit from stronger dollar?

TheStreet Quant Rating: C (Hold)